An Open-Label Multicenter 3-Arm Randomized Phase 2 Study to Assess the Efficacy and Safety of TTX-030 and Chemotherapy With or Without Budigalimab, Compared to Chemotherapy Alone, for the Treatment of Patients not Previously Treated for Metastatic Pancreatic Adenocarcinoma - TTX-030-003

Trishula Therapeutics Inc.0 个研究点目标入组 173 人开始时间: 2024年2月6日最近更新: 2024年8月21日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方: Trishula Therapeutics Inc.
入组人数: 173

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol., Subject must weigh =35 kg., Resolution of adverse events from any prior chemotherapy, immunotherapy, or prior systemic anticancer therapy, radiotherapy, or surgery to Grade 1 or baseline (except Grade 2 alopecia and Grade 2 sensory neuropathy)., Women of childbearing potential and all men must agree to use 2 highly effective methods of contraception through 6 months (180 days) after the last administration of any study treatment. Note: Highly effective contraception methods include total abstinence; female sterilization (tubal ligation, bilateral oophorectomy, and/or hysterectomy); male sterilization (at least 6 months prior to Screening); intrauterine device or intrauterine hormone-releasing system; oral, injected, or implanted hormonal contraception with only progestogen at least 30 days before first dose; AND barrier methods of contraception; oral, injectable, transdermal, or intravaginal combined hormonal contraception with estrogen and progestogen at least 30 days before first dose (Prescribing information should be followed if different from the above)., Subjects with history of congestive heart failure must have cardiac echocardiogram (ECHO) or multigated acquisition (MUGA) scan indicating left ventricular ejection fraction =45% within 28 days prior to the first dose of study treatment., Required baseline laboratory tests: a. Hematology: absolute neutrophil count (ANC) =1.2 k/µL, platelets =100 k/µL, hemoglobin (Hgb) =9 g/dL b. Coagulation: prothrombin time (PT) and International Normalized Ratio (INR) =1.2 x upper limit of normal (ULN), except for subjects receiving anticoagulation; subjects must be on a stable dose of warfarin for 6 weeks prior to enrollment. c. Kidney: Creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) =40 mL/min calculated by Cockcroft-Gault or CKD-EPI (Appendix 6) d. Liver: AST and ALT =2.5 x ULN (or =5 x ULN with hepatic metastases); total bilirubin =2 x ULN (or =3 x ULN with Gilbert’s syndrome); serum albumin =3.0 g/dL, Male or female subjects =18 years of age at the time of screening., Histologically or cytologically confirmed diagnosis of metastatic PDAC., No prior systemic treatment for metastatic disease. Prior neoadjuvant or adjuvant systemic chemotherapy is permitted in the absence of disease progression within 6 months following last dose of chemotherapy., No prior treatment with therapeutics specifically targeted to enhancing or de-repressing anti-tumor immunity including but not limited to checkpoint inhibitors or agents targeting the adenosine pathway (CD39, CD73 or adenosine receptor inhibitors)., Evidence of measurable disease as assessed by the investigator per RECIST 1.1., Appropriate for treatment with nab-paclitaxel and gemcitabine chemotherapy., Availability of tumor tissue (obtained by biopsy during screening, or archival if collected within 90 days prior to the first dose of study drug and in the absence of intervening therapy). Subjects with contraindications for a biopsy procedure and without acceptable archival tissue samples are not eligible., Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

排除标准

•History of clinically significant allergy or hypersensitivity to planned study treatment components or to any monoclonal antibody (defined as any Grade 3 reaction lasting =48 hours despite optimal therapy), Subject has received live vaccine within 28 days prior to the first dose of study drug, The subject has had major surgery per the Investigator within 28 days prior to the first dose of study drug, and the surgical wound is not adequately healed. A diagnostic or research biopsy does not exclude subjects from enrollment. Placement of a vascular access device such as a Port-A-Cath is not considered major surgery., Has uncontrolled intercurrent illness including, but not limited to: a. Uncontrolled diabetes b. New York Heart Association (NYHA) Class 3 or 4 congestive heart failure c. Unstable angina, arrhythmia, or myocardial infarction within 6 months prior to screening d. Poorly controlled hypertension, defined as a blood pressure consistently above 160/90 mmHg despite optimal medical management e. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage more than once every 28 days. Indwelling drainage catheters (e.g., PleurX®) are allowed f. Active or chronic viral hepatitis B or C infection g. Uncontrolled thyroid disease h. Active infection requiring systemic therapy; subjects receiving ongoing systemic antibiotic, antiviral or antifungal therapy for maintenance should be discussed with the medical monitor prior to screening and enrollment, History of SJS, Toxic epidermal necrolysis (TEN), or drug reaction with eosinophilia and systemic symptoms (DRESS), History of autoimmune disease including but not limited to rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, non-infectious pneumonitis, interstitial lung disease (ILD), requiring systemic treatment that required systemic steroids or immunosuppressive agents within the last 2 years. Subjects with findings consistent with active autoimmune disease on screening evaluation (computed tomography [CT] showing pneumonitis or ILD, physical examination findings) are not eligible. NOTE: History of vitiligo, autoimmune thyroiditis, or mild psoriasis are allowed., Any active disease requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days prior to Day 1 of treatment. (NOTE: Inhaled, intranasal, intra-articular and topical [including ocular] steroids are allowed. Adrenal replacement [i.e., physiologic replacement] doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease)., History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis, Use of investigational agent within 14 days prior to the first dose of study drug, Evidence of active central nervous system (CNS) metastatic disease or carcinomatous meningitis, Known history of human immunodeficiency virus (HIV) or other chronic immunodeficiency, Women who are pregnant or breastfeeding

研究者

发起方

Trishula Therapeutics Inc.

相似试验

进行中（未招募）

1 期

A Phase 3 Trial of Alisertib (MLN8237) or Investigator's Choice (SelectedSingle Agent) in Patients With Relapsed or Refractory Peripheral T-CellLymphoma.Relapsed or Refractory Peripheral T-Cell LymphomaMedDRA version: 17.0Level: PTClassification code 10034629Term: Peripheral T-cell lymphoma unspecified stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10034628Term: Peripheral T-cell lymphoma unspecified stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10034627Term: Peripheral T-cell lymphoma unspecified stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10034626Term: Peripheral T-cell lymphoma unspecified refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10034625Term: Peripheral T-cell lymphoma unspecified recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10034630Term: Peripheral T-cell lymphoma unspecified stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10034623Term: Peripheral T-cell lymphoma unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2011-003545-18-SEMillennium Pharmaceuticals, Inc354

进行中（未招募）

1 期

A Phase 3 Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

EUCTR2011-003545-18-DEMillennium Pharmaceuticals, Inc354

进行中（未招募）

1 期

EUCTR2011-003545-18-ATMillennium Pharmaceuticals, Inc354

进行中（未招募）

1 期

A Phase 3 Trial of Alisertib (MLN8237) or Investigator's Choice (SelectedSingle Agent) in Patients With Relapsed or Refractory Peripheral T-CellLymphoma.

EUCTR2011-003545-18-HUMillennium Pharmaceuticals, Inc354

进行中（未招募）

1 期

A Phase 3 Trial of Alisertib (MLN8237) or Investigator's Choice (SelectedSingle Agent) in Patients With Relapsed or Refractory Peripheral T-CellLymphoma.

EUCTR2011-003545-18-CZMillennium Pharmaceuticals, Inc354